遺伝性血管性浮腫(Hereditary Angioedema (HAE)):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Hereditary Angioedema (HAE) - Pipeline Review, H2 2014
◆商品コード:GMDHC5702IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における遺伝性血管性浮腫(Hereditary Angioedema (HAE))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・遺伝性血管性浮腫(Hereditary Angioedema (HAE))の概要
・遺伝性血管性浮腫(Hereditary Angioedema (HAE))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・遺伝性血管性浮腫(Hereditary Angioedema (HAE))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・遺伝性血管性浮腫(Hereditary Angioedema (HAE))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・遺伝性血管性浮腫(Hereditary Angioedema (HAE))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hereditary Angioedema (HAE) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hereditary Angioedema (HAE) – Pipeline Review, H2 2014’, provides an overview of the Hereditary Angioedema (HAE)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hereditary Angioedema (HAE) Overview 7
Therapeutics Development 8
Pipeline Products for Hereditary Angioedema (HAE) – Overview 8
Pipeline Products for Hereditary Angioedema (HAE) – Comparative Analysis 9
Hereditary Angioedema (HAE) – Therapeutics under Development by Companies 10
Hereditary Angioedema (HAE) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hereditary Angioedema (HAE) – Products under Development by Companies 15
Hereditary Angioedema (HAE) – Companies Involved in Therapeutics Development 16
BioCryst Pharmaceuticals, Inc. 16
Cevec Pharmaceuticals GmbH 17
CSL Limited 18
Dyax Corp. 19
Global Blood Therapeutics, Inc. 20
iBio, Inc. 21
Isis Pharmaceuticals, Inc. 22
Pharming Group N.V. 23
Ra Pharmaceuticals, Inc. 24
Shire Plc 25
Hereditary Angioedema (HAE) – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
BCX-4161 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BEL-0215 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
C1 esterase inhibitor (human) – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C1 esterase inhibitor (human) – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
C1 esterase inhibitor (human) – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
C1 esterase inhibitor (recombinant) – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CSL-3F7 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cyclomimetic – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DX-2930 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
icatibant acetate – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ISIS-PKKRx – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Peptide to Inhibit Kallikrein for Hereditary Angioedema – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule 1 to Inhibit Plasma Kallikrein for Hereditary Angioedema – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule for Hereditary Angioedema – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Hereditary Angioedema (HAE) – Recent Pipeline Updates 58
Hereditary Angioedema (HAE) – Dormant Projects 68
Hereditary Angioedema (HAE) – Product Development Milestones 69
Featured News & Press Releases 69
Nov 04, 2014: Pharming Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals 69
Nov 03, 2014: Salix and Pharming Announce the Launch of RUCONEST in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE) 69
Nov 03, 2014: Dyax Announces Expansion of Phase 1b Clinical Trial for DX-2930 70
Oct 13, 2014: Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement 71
Oct 07, 2014: BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress 71
Sep 15, 2014: Dyax Announces Issuance of Two Key U.S. Patents for DX-2930 72
Aug 28, 2014: Pharming and Salix Announce Initiation of Clinical Study of RUCONEST for Prophylaxis of Hereditary Angioedema 72
Jul 30, 2014: Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 73
Jul 23, 2014: Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals 74
Jul 17, 2014: Salix and Pharming Announce FDA Approval of RUCONEST for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

[List of Tables]
Number of Products under Development for Hereditary Angioedema (HAE), H2 2014 8
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Hereditary Angioedema (HAE) - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014 16
Hereditary Angioedema (HAE) - Pipeline by Cevec Pharmaceuticals GmbH, H2 2014 17
Hereditary Angioedema (HAE) - Pipeline by CSL Limited, H2 2014 18
Hereditary Angioedema (HAE) - Pipeline by Dyax Corp., H2 2014 19
Hereditary Angioedema (HAE) - Pipeline by Global Blood Therapeutics, Inc., H2 2014 20
Hereditary Angioedema (HAE) - Pipeline by iBio, Inc., H2 2014 21
Hereditary Angioedema (HAE) - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 22
Hereditary Angioedema (HAE) - Pipeline by Pharming Group N.V., H2 2014 23
Hereditary Angioedema (HAE) - Pipeline by Ra Pharmaceuticals, Inc., H2 2014 24
Hereditary Angioedema (HAE) - Pipeline by Shire Plc, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Hereditary Angioedema (HAE) Therapeutics - Recent Pipeline Updates, H2 2014 58
Hereditary Angioedema (HAE) - Dormant Projects, H2 2014 68

[List of Figures]
Number of Products under Development for Hereditary Angioedema (HAE), H2 2014 8
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Top 10 Targets, H2 2014 27
Number of Products by Stage and Top 10 Targets, H2 2014 28
Number of Products by Top 10 Mechanism of Actions, H2 2014 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Top 10 Routes of Administration, H2 2014 31
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 32
Number of Products by Top 10 Molecule Types, H2 2014 33
Number of Products by Stage and Top 10 Molecule Types, H2 2014 34

【掲載企業】

BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[遺伝性血管性浮腫(Hereditary Angioedema (HAE)):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆